Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

Correction for Wolff et al., "Cell-Type-Dependent Regulation of mTORC1 by REDD1 and the Tumor Suppressors TSC1/TSC2 and LKB1 in Response to Hypoxia".

Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, Castrillon DH, Kabbani W, Brugarolas J.

Mol Cell Biol. 2017 Jun 15;37(13). pii: e00224-17. doi: 10.1128/MCB.00224-17. Print 2017 Jul 1. No abstract available.

2.

Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.

Cao L, Li LS, Spruell C, Xiao L, Chakrabarti G, Bey EA, Reinicke KE, Srougi MC, Moore Z, Dong Y, Vo P, Kabbani W, Yang CR, Wang X, Fattah F, Morales JC, Motea EA, Bornmann WG, Yordy JS, Boothman DA.

Antioxid Redox Signal. 2014 Jul 10;21(2):237-50. doi: 10.1089/ars.2013.5462. Epub 2014 Apr 3.

3.

A polyp from another polyp.

Kuo V, Kabbani W, Linder J.

Can J Gastroenterol. 2013 Dec;27(12):686. No abstract available.

4.

Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes.

Rink M, Xylinas E, Trinh QD, Lotan Y, Margulis V, Raman JD, Fisch M, Lee RK, Chun FK, Abdennabi J, Seitz C, Pycha A, Zlotta AR, Karakiewicz PI, Babjuk M, Scherr DS, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration (UTUCC).

BJU Int. 2013 Sep;112(5):623-37. doi: 10.1111/bju.12014. Epub 2013 Mar 6.

5.

Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy.

Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, Chun FK, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood CG, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration.

Eur Urol. 2013 Jun;63(6):1082-90. doi: 10.1016/j.eururo.2012.06.029. Epub 2012 Jun 22.

6.

Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma.

Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, Shariat SF.

J Urol. 2012 Aug;188(2):398-404. doi: 10.1016/j.juro.2012.04.009. Epub 2012 Jun 13.

PMID:
22698626
7.

BAP1 loss defines a new class of renal cell carcinoma.

Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, Kinch L, Hambuch T, Jain S, Lotan Y, Margulis V, Sagalowsky AI, Summerour PB, Kabbani W, Wong SW, Grishin N, Laurent M, Xie XJ, Haudenschild CD, Ross MT, Bentley DR, Kapur P, Brugarolas J.

Nat Genet. 2012 Jun 10;44(7):751-9. doi: 10.1038/ng.2323. Erratum in: Nat Genet. 2012 Sep;44(9):1072.

8.

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma.

Sivanand S, Peña-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, Yamasaki T, McBride DJ, Gillen J, Wolff NC, Morlock L, Lotan Y, Raj GV, Sagalowsky A, Margulis V, Cadeddu JA, Ross MT, Bentley DR, Kabbani W, Xie XJ, Kapur P, Williams NS, Brugarolas J.

Sci Transl Med. 2012 Jun 6;4(137):137ra75. doi: 10.1126/scitranslmed.3003643.

9.

Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.

Youssef R, Kapur P, Shariat SF, Arendt T, Kabbani W, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y.

BJU Int. 2012 Oct;110(7):961-6. doi: 10.1111/j.1464-410X.2012.10949.x. Epub 2012 Feb 28.

10.

Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery.

Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, Shariat SF; Bladder Cancer Research Consortium (BCRC); Upper Tract Urothelial Carcinoma Collaboration (UTUCC).

Eur Urol. 2012 Oct;62(4):677-84. Epub 2012 Feb 15.

PMID:
22349570
11.

Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification.

Shariat SF, Zigeuner R, Rink M, Margulis V, Hansen J, Kikuchi E, Kassouf W, Raman JD, Remzi M, Koppie TM, Bensalah K, Guo CC, Mikami S, Sircar K, Ng CK, Haitel A, Kabbani W, Chun FK, Wood CG, Scherr DS, Karakiewicz PI, Langner C.

Eur Urol. 2012 Aug;62(2):224-31. doi: 10.1016/j.eururo.2012.01.019. Epub 2012 Jan 24.

PMID:
22285763
12.

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

Kucejova B, Peña-Llopis S, Yamasaki T, Sivanand S, Tran TA, Alexander S, Wolff NC, Lotan Y, Xie XJ, Kabbani W, Kapur P, Brugarolas J.

Mol Cancer Res. 2011 Sep;9(9):1255-65. doi: 10.1158/1541-7786.MCR-11-0302. Epub 2011 Jul 28.

13.

Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers.

Kapur P, Lotan Y, King E, Kabbani W, Mitra AP, Mosbah A, Abol-Enein H, Ghoneim M, Youssef RF.

Am J Clin Pathol. 2011 Jun;135(6):822-30. doi: 10.1309/AJCP76KUVOTBKQRY.

PMID:
21571954
14.

Tissue compression analysis for magnetically anchored cautery dissector during single-site laparoscopic cholecystectomy.

Mashaud LB, Kabbani W, Caban A, Best S, Hogg DC, Cadeddu JA, Bergs R, Beardsley H, Fernandez R, Scott DJ.

J Gastrointest Surg. 2011 Jun;15(6):902-7. doi: 10.1007/s11605-011-1491-0. Epub 2011 Apr 12.

PMID:
21484494
15.

Urinary cytology for the detection of urothelial carcinoma of the bladder--a flawed adjunct to cystoscopy?

Bolenz C, West AM, Ortiz N, Kabbani W, Lotan Y.

Urol Oncol. 2013 Apr;31(3):366-71. doi: 10.1016/j.urolonc.2011.01.017. Epub 2011 Mar 16.

PMID:
21414815
16.

Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia.

Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, Castrillon DH, Kabbani W, Brugarolas J.

Mol Cell Biol. 2011 May;31(9):1870-84. doi: 10.1128/MCB.01393-10. Epub 2011 Mar 7. Erratum in: Mol Cell Biol. 2017 Jun 15;37(13):.

17.

Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration.

Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Kabbani W, Langner C, Guo CC, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V.

BJU Int. 2011 Oct;108(8):1286-91. doi: 10.1111/j.1464-410X.2011.10075.x. Epub 2011 Feb 18.

18.

Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder.

Youssef RF, Shariat SF, Kapur P, Kabbani W, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y.

J Urol. 2011 Mar;185(3):1112-7. doi: 10.1016/j.juro.2010.10.036. Epub 2011 Jan 21.

PMID:
21255800
19.

Effect of the Bethesda system for reporting thyroid cytopathology on thyroidectomy rates and malignancy risk in cytologically indeterminate lesions.

Rabaglia JL, Kabbani W, Wallace L, Holt S, Watumull L, Pruitt J, Snyder WH, Nwariaku FE.

Surgery. 2010 Dec;148(6):1267-72; discussion 1272-3. doi: 10.1016/j.surg.2010.09.017.

PMID:
21134560
20.

Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder.

Youssef RF, Shariat SF, Kapur P, Kabbani W, Ghoneim T, King E, Cockburn A, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y.

Hum Pathol. 2011 Mar;42(3):347-55. doi: 10.1016/j.humpath.2010.07.012. Epub 2010 Nov 26.

PMID:
21111452

Supplemental Content

Loading ...
Support Center